Hwangseo Park is a Professor in the Department of Integrative Bioscience and Biotechnology at Sejong University, with an active research profile evidenced by 144 publications and an h-index of 35. Current research output spans from 1997 to 2025, showing sustained productivity with 5 publications in 2025 alone. Research focuses on computational drug discovery and structural biology , particularly targeting enzyme inhibition mechanisms. Key areas include virtual screening, protein tyrosine phosphatase modulation, de novo drug design, and nanobody-based therapeutics. The fingerprint analysis reveals dominant work in pharmacology (100% Virtual Screening), biochemistry (52% Active Site studies), and molecular biology (46% Phosphatase research). Recent publications demonstrate strong translational impact, with 2025 papers covering Pancreatic cancer therapy via mesothelin-targeting nanobodies (cited 2 times) CD155-targeted lung adenocarcinoma treatment (6 news mentions) Vaspin-AP-1 axis blockade for arthritis (featured in news outlets) IRAK4 inhibitor optimization for anti-inflammatory applications Green space health impact analysis using digital tracking These works show consistent focus on structure-based therapeutic development with increasing clinical relevance. No formal awards are documented in the provided materials. Research activities involve significant international collaboration, with network visualizations indicating multi-country partnerships in pharmacology and biochemistry domains. Current projects emphasize nanobody engineering for precision oncology and computational optimization of drug candidates.










